SAN DIEGO, Aug. 31, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO™), the leader in accelerating global development of China's pharmaceutical innovations, announced today the filing of an investigational new drug application (IND) with the FDA for HBI-2376 along with Genhouse who has filed an IND with the Chinese Center for Drug Excellence CDE.
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- HUYA Bioscience International (HUYABIOTM), the leader in accelerating global development of China's pharmaceutical innovations, today announced the presentation of results from an ongoing Phase II study evaluating the efficacy and safety of HBI-8000 in combination with nivolumab in patients with advanced metastatic melanoma. The results were presented at the Society for Immunotherapy of Cancer's virtual 35th Anniversary Annual Meeting (SITC 2020; Abstract # 797).
SAN DIEGO, CA, USA – August 4, 2020 HUYA Bioscience International (HUYABIO®), the leader in accelerating global development of China’s pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, outside of China, to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse.
® ), the leader in accelerating global development of China's pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, outside of China, to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse.